Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, has celebrated the grand opening of its new state-of-the-art manufacturing facility in Mesa, for the company’s growing continuous glucose monitoring (CGM) business. This new 180,000-square-foot facility, at 232 S. Dobson Road, will support the company’s global manufacturing operations and is projected to create more than 500 jobs over the next several years.
Diabetes affects 29.1 million Americans and is the seventh leading cause of death in the United States. With diabetes, the body cannot produce or use the hormone insulin effectively, causing a buildup of glucose, or sugar, in the blood. Obesity, physical inactivity and poor diet are risk factors for the development of diabetes. People with diabetes who take insulin must monitor their blood glucose levels frequently. Uncontrolled glucose can cause health complications and even death.
Advances in technology have helped those with diabetes stay on top of their glucose levels. Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years. With the recent introduction of the Dexcom G5 Mobile CGM System, people with diabetes can now view their glucose information on their iOS-enabled devices for real-time diabetes management. CGM is important because, in addition to providing the glucose level, it provides the direction and rate of glucose change with the push of a button and alerts users when glucose is too low or too high.